Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Seeking Alpha / 3 hours ago 1 Views

Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications 
Company initiates formal regulatory engagement on trial design  for Alzheimer’s, dementia, and MCI indications
Read more

Comments